A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine
Crossref DOI link: https://doi.org/10.1186/s10194-017-0740-3
Published Online: 2017-03-01
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Munjal, Sagar
Brand-Schieber, Elimor
Allenby, Kent
Spierings, Egilius L.H.
Cady, Roger K.
Rapoport, Alan M.
License valid from 2017-03-01